ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
| Website: | www.chromadex.com |
| Email: | InvestorRelations@chromadex.com |
| Main Phone: | +949.419.0288 ext. 127 |
| Address: | 10900 Wilshire Boulevard |
| Address 2: | Suite 650 |
| State: | CA |
| City / Town: | Los Angeles |
| Country: | US |
| Postal Code: | 90024 |
| Exchange: | NSC |
| CEO: | Robert N. Fried |
| Employees: | 110 |
| NAICS: | Medicinal and Botanical Manufacturing(325411) |
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
| Website: | www.chromadex.com |
| Email: | InvestorRelations@chromadex.com |
| Main Phone: | +949.419.0288 ext. 127 |
| Address: | 10900 Wilshire Boulevard |
| Address 2: | Suite 650 |
| State: | CA |
| City / Town: | Los Angeles |
| Country: | US |
| Postal Code: | 90024 |
| Exchange: | NSC |
| CEO: | Robert N. Fried |
| Employees: | 110 |
| NAICS: | Medicinal and Botanical Manufacturing(325411) |
| Last Price 5.01 | Change $ 0.15 | Change % 3.09 | Tick N/A |
| Bid 4.95 | Bid Size 4,200.00 | Ask 4.96 | Ask Size 1,300.00 |
| Open 4.86 | High 5.07 | Low 4.86 | Prev Close 4.86 |
| Last Trade | Volume 167,688 | 52 Wk Hi 6.00 | 52 Wk Low 2.50 |
| Market Cap 309.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 61,787,728.00 | EPS (TTM) -0.38 | PE Ratio -12.80 | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 10 | 19 |
| Number of Buys | 8 | 14 |
| Number of Sells | 2 | 5 |
| Net Activity | 37800 | 383133 |
| Last 10 Buys | Shares |
|---|---|
| Kevin M. Farr | 1,000 |
| Mark J. Friedman | 1,000 |
| Frank L. Jaksch | 1,000 |
| Robert N. Fried | 1,000 |
| Frank L. Jaksch | 1,000 |
| Stephen Allen | 1,000 |
| Robert N. Fried | 1,000 |
| Stephen Allen | 1,000 |
| Stephen Allen | 1,000 |
| Frank L. Jaksch | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Frank L. Jaksch | 1,000 |
| Frank L. Jaksch | 1,000 |
| Frank L. Jaksch | 1,000 |
| Frank L. Jaksch | 1,000 |
| Frank L. Jaksch | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 10.5 | 10.5 | 10.5 | 10.5 |
| Low Target Price Estimate | 8 | 8 | 8 | 8 |
| Mean Target Price Estimate | 9.25 | 9.25 | 9.25 | 9.25 |
| Standard Deviation | 1.77 | 1.77 | 1.77 | 1.77 |
| Date of Most Recent Estimate | 05/24/18 | 05/24/18 | 03/11/18 | 05/24/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-06-06 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-16 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-16 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 27 | 2018-05-10 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 49 | 2018-05-10 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait